Reuters logo
Gilead says on track with hepatitis C treatments
January 7, 2013 / 2:40 PM / 5 years ago

Gilead says on track with hepatitis C treatments

(Reuters) - Gilead Sciences Inc is on track to file for regulatory approval of sofosbuvir, its treatment for chronic hepatitis C virus (HCV) infection, starting in mid-2013, the biotech company said on Monday.

Gilead is scheduled to give investors an update on its candidates for HCV treatment at a JPMorgan healthcare conference this week in San Francisco.

The company will discuss new results from an arm of a continuing Phase 2 trial and provide a progress report on a range of Phase 2 and 3 trials evaluating a once-daily fixed-dose combination tablet of the medicines.

Reporting by Debra Sherman; editing by John Wallace

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below